StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.79−0.08 (-0.27%)

Close on Nov 18, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

UroGen Pharma's operating income for the twelve months ending Jun 30, 2026 was -$66.65M. For fiscal 2025 it was -$124.86M. The highest annual figure on record is $798.00K in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$124.86M–
FY2024Dec 31, 2024-$96.78M–
FY2023Dec 31, 2023-$65.54M–
FY2022Dec 31, 2022-$79.04M–
FY2021Dec 31, 2021-$92.29M–
FY2020Dec 31, 2020-$126.74M–
FY2019Dec 31, 2019-$109.48M–
FY2018Dec 31, 2018-$77.18M–
FY2017Dec 31, 2017-$19.95M-2600.0%
FY2016Dec 31, 2016$798.00K–
FY2015Dec 31, 2015-$12.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$111.00K–
Q1 FY2026Mar 31, 2026-$20.26M–
Q4 FY2025Dec 31, 2025-$19.12M–
Q3 FY2025Sep 30, 2025-$27.39M–
Q2 FY2025Jun 30, 2025-$41.45M–
Q1 FY2025Mar 31, 2025-$36.91M–
Q4 FY2024Dec 31, 2024-$27.66M–
Q3 FY2024Sep 30, 2024-$17.55M–
Q2 FY2024Jun 30, 2024-$25.84M–
Q1 FY2024Mar 31, 2024-$25.74M–
Q4 FY2023Dec 31, 2023-$14.61M–
Q3 FY2023Sep 30, 2023-$13.50M–
Q2 FY2023Jun 30, 2023-$15.38M–
Q1 FY2023Mar 31, 2023-$22.05M–
Q4 FY2022Dec 31, 2022-$20.28M–
Q3 FY2022Sep 30, 2022-$18.09M–
Q2 FY2022Jun 30, 2022-$18.72M–
Q1 FY2022Mar 31, 2022-$21.96M–
Q4 FY2021Dec 31, 2021-$19.92M–
Q3 FY2021Sep 30, 2021-$23.44M–
Q2 FY2021Jun 30, 2021-$22.82M–
Q1 FY2021Mar 31, 2021-$26.11M–
Q4 FY2020Dec 31, 2020-$27.25M–
Q3 FY2020Sep 30, 2020-$29.12M–
Q2 FY2020Jun 30, 2020-$31.80M–
Q1 FY2020Mar 31, 2020-$38.56M–
Q4 FY2019Dec 31, 2019-$39.84M–
Q3 FY2019Sep 30, 2019-$23.45M–
Q2 FY2019Jun 30, 2019-$23.75M–
Q1 FY2019Mar 31, 2019-$22.43M–
Q4 FY2018Dec 31, 2018-$24.02M–
Q3 FY2018Sep 30, 2018-$21.09M–
Q2 FY2018Jun 30, 2018-$18.43M–
Q1 FY2018Mar 31, 2018-$13.64M–
Q4 FY2017Dec 31, 2017-$10.16M–
Q3 FY2017Sep 30, 2017-$303.00K–
Q2 FY2017Jun 30, 2017-$5.95M–
Q1 FY2017Mar 31, 2017-$3.54M–

More UroGen Pharma figures

See a number that looks wrong?